Skip to main content
NewslettersWatchlist

Fibrogen Inc CS(FGEN-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time

FibroGen Announces Completion of Patient Enrollment in ZEPHYRUS-1, a Phase 3 Clinical Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis

Globe Newswire - Wed Apr 20, 2022

- 356 IPF Patients Enrolled -

- Topline Data Anticipated Mid-2023 -

SAN FRANCISCO, April 20, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced completion of patient enrollment for ZEPHYRUS-1, the first of two Phase 3 clinical studies of pamrevlumab in patients with idiopathic pulmonary fibrosis (IPF), a chronic, progressive, and fatal lung disease.

Read more at globenewswire.com

Provided Content: Content provided by Globe Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.

More from The Globe

opinion
This Canadian aerospace stock deserves a place on your watch list
Robert Tattersall
market news
The close: TSX pulls back as resource shares slide; Nvidia rallies in post market on earnings beat
Traders work on the floor of the New York Stock Exchange during morning trading on May 17.
inside the market
What every Canadian investor needs to know today
A screen tracks NVIDIA Corp. as a trader works on the floor at the New York Stock Exchange (NYSE) in New York City, U.S., October 23, 2023. REUTERS/Brendan McDermid/File Photo
globe investor
Earnings from AI-heavyweight Nvidia to test U.S. stocks’ record run
A sign is posted in front of Nvidia headquarters on May 21 in Santa Clara, California.
market news
The close: S&P 500 and TSX squeak out record highs after Fed comments
The Art Deco facade of the original Toronto Stock Exchange building is seen on Bay Street in Toronto in January of 2019.
inside the market
Before the Bell: What every Canadian investor needs to know today
Traders work on the floor of the New York Stock Exchange during morning trading on May 17, 2024 in New York City. Wall Street stocks opened little changed May 17 after pulling back from a record run where the Dow exceeded 40,000 points for the first time. Around 10 minutes into trading the Dow Jones Industrial Average was steady at 39,872.66. (Photo by ANGELA WEISS / AFP) (Photo by ANGELA WEISS/AFP via Getty Images)
report on business
ReconAfrica agrees to pay out more than $10-million over allegedly misleading disclosure
ReconAfrica oil drilling site in Namibia for Geoffrey York and Emma Graney story.
number cruncher
U.S technology stocks with earnings and price momentum
For Number Cruncher column in Globe Investor/ROB only.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).